A Japanese health ministry panel will meet on June 29 to discuss whether to recommend approval for Janssen Pharmaceutical’s CAR-T cell therapy Carvykti (ciltacabtagene autoleucel) for earlier-line use in multiple myeloma. Carvykti is a B-cell maturation antigen (BCMA)-targeted CAR-T therapy…
To read the full story
Related Article
- Janssen’s CAR-T Therapy Carvykti Approved in Japan
September 27, 2022
REGULATORY
- Yoshida Pharma Plant Hit with Improvement Order over Testing Violations
June 23, 2026
- Carvykti Earlier Use Up for Japan Panel Review on June 29
June 23, 2026
- Japan Approves Wegovy MASH Use, AstraZeneca’s Etcamah, Others
June 22, 2026
- Japan on Alert over US MFN Drug Pricing Policy: Health Minister
June 22, 2026
- Japan Restarts Deliberations on Routine Mumps Vaccination, Eyes FY2027 Rollout
June 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





